Liability Related to Sale of Future Revenues - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 04, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		$ 40,134,000	$ 15,735,000	$ 120,614,000	$ 106,367,000
NovaQuest Capital Management [Member] \| Revenue Interest Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Effective annual interest rate related to sale of future revenues				16.07%
NovaQuest Capital Management [Member] \| Revenue Interest Financing Agreement [Member] \| Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepayment amount of 2024 to 2030	$ 80,000,000
NovaQuest Capital Management [Member] \| Revenue Interest Financing Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepayment amount of 2024 to 2030	125,000,000
NovaQuest Capital Management [Member] \| Payment Period One [Member] \| Revenue Interest Financing Agreement [Member] \| Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue interest payment	62,500,000
NovaQuest Capital Management [Member] \| Payment Cap Date on or before December 31, 2028 [Member] \| Revenue Interest Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment cap amount	100,000,000
NovaQuest Capital Management [Member] \| Payment Cap Date on or after January 1, 2029 [Member] \| Revenue Interest Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment cap amount	112,500,000
NovaQuest Capital Management [Member] \| Payment Cap Date after January 1, 2030 [Member] \| Revenue Interest Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment cap amount	125,000,000
NovaQuest Capital Management [Member] \| Payment Period Two [Member] \| Revenue Interest Financing Agreement [Member] \| Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue interest payment	125,000,000
Product [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		29,390,000	17,359,000	$ 77,439,000	59,495,000
Product [Member] \| NovaQuest Capital Management [Member] \| Revenue Interest Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue interest payment	10,000,000
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		2,649,000	0	9,649,000	22,590,000
Other Revenue - Contract Manufacturing [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		6,775,000	2,453,000	15,825,000	19,672,000
Astellas Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future revenue granted	$ 50,000,000
Percentage of revenue interest on global net sales	100.00%
Astellas Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue payment cap amount						$ 125,000,000
Astellas Agreement [Member] \| Product [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue sold	22.50%
Astellas Agreement [Member] \| Milestone payments [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue sold	10.00%
Astellas Agreement [Member] \| Milestone payments [Member] \| Payment Period One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue sold	20.00%
Development Revenue [Member] \| Astellas Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		2,400,000		5,800,000
Drug Product Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		1,320,000	$ (4,077,000)	17,701,000	$ 4,610,000
Drug Product Revenue [Member] \| Astellas Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		1,300,000		17,700,000
Non-cash interest expense related to drug product revenue		$ 2,100,000		$ 5,600,000